Abstract
Pharmacotherapy of multiple sclerosis (MS) is evolving rapidly. Despite impressive gains over the past 2 decades in the approval of multiple drugs for MS, lack of recruitment of minorities with MS in phase 3 clinical studies is a persistent concern and skews efficacy and disability data.
Keywords:
African-American MS; FDA; clinical trials; disability; disease modifying drugs; post-marketing data analysis.
MeSH terms
-
Antibodies, Monoclonal, Humanized / adverse effects*
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Black or African American*
-
Daclizumab / adverse effects*
-
Daclizumab / therapeutic use
-
Humans
-
Multiple Sclerosis / drug therapy*
-
Product Surveillance, Postmarketing / standards*
-
Product Surveillance, Postmarketing / statistics & numerical data
-
Selection Bias
-
United States
-
United States Food and Drug Administration / standards
Substances
-
Antibodies, Monoclonal, Humanized
-
ocrelizumab
-
Daclizumab